Compare Bristol-Myers Squibb Co (BMY) vs iShares MSCI Japan ETF (EWJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares MSCI Japan ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.79 (market cap $116.30B), while iShares MSCI Japan ETF trades at $92.87. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals.
| BMY | EWJ | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $62.37 | $96.97 |
52-Week Low | $42.60 | $71.81 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
EWJ, the iShares MSCI Japan ETF, trades at $92.72, down 1.94% on the day. Technical indicators are mixed, with a neutral overall signal but bullish moving averages, while key financial ratios are unavailable. The ETF provides exposure to Japanese equities but faces headwinds from yen weakness, as recent news highlights currency hedging strategies and potential government intervention to support the yen.
The outlook for EWJ is influenced by Japan's equity market performance and currency dynamics. Opportunities include diversification benefits and potential gains if the Nikkei 225 rebounds, but risks stem from yen depreciation, geopolitical tensions, and domestic economic policies. Investors should weigh currency-hedged alternatives amid ongoing volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →
